BioCentury
ARTICLE | Strategy

Genmab's platform decisions

October 20, 2008 7:00 AM UTC

Just about every biotech company nearing commercialization finds that it has to rejigger its spending - both to account for the costs of market launch and to meet investors' expectations about delivering earnings. Genmab A/S is one of the first high profile biotechs to reach this inflection point in the new, more stringent, regulatory and payer environment, and the antibody company has proactively refocused its pipeline to meet the needs of this new world.

Genmab, which plans its first BLA submission around year end, needed to balance its R&D spend with expected revenue to become a sustainable company. The results of its review, announced earlier this month, include dropping programs in small markets or outside its core area of cancer so it can focus on projects with the highest market potential...